Shantha Biologics and Novo Nordisk Sign Cartridge Fill-Finish Agreement
Shantha Biologics, a Hyderabad-based pharmaceutical manufacturing company, announced on July 1, 2026, that it has entered into an outsourcing agreement with global healthcare leader Novo Nordisk to provide cartridge fill-finish manufacturing services in India. The collaboration underscores Shantha Biologics' commitment to high-quality manufacturing and its role as a trusted partner for international pharmaceutical companies.
Details of the Collaboration
The agreement will be governed by a contractual framework agreed upon by both parties, ensuring adherence to applicable quality, compliance, and regulatory requirements. No financial terms or further specifics of the deal have been disclosed, as per the company's statement.
Dr. Vishy Chebrol, Director of Shantha Biologics, commented, "We are pleased to enter into this collaboration, which reflects the confidence placed in Shantha Biologics' capabilities and our commitment to reliable, high-quality cartridge fill-finish services. We look forward to supporting this partnership through strong operational execution and a continued focus on quality and compliance."
Shantha Biologics' Manufacturing Capabilities
Shantha Biologics, based in Hyderabad, Telangana, India, specializes in vaccines, biologics, and specialized sterile manufacturing. The company operates purpose-built sterile fill-finish capacity, including cartridge filling, and partners with global pharmaceutical and biotechnology companies to deliver high-quality development and aseptic manufacturing that meets international standards.
This agreement with Novo Nordisk marks a significant step for Shantha Biologics in expanding its role as a contract manufacturing organization (CMO) for injectable drug products. The company's focus on quality and compliance aligns with the stringent requirements of global pharmaceutical supply chains.
Industry Context and Impact
The collaboration comes at a time when demand for sterile fill-finish services, particularly for cartridge-based drug delivery systems, is growing due to the rise of biologics and injectable therapies. Novo Nordisk, a Danish multinational known for diabetes care and other chronic diseases, benefits from Shantha Biologics' manufacturing expertise in India, a key hub for pharmaceutical production.
By leveraging Shantha Biologics' facilities, Novo Nordisk can enhance its supply chain resilience and capacity for cartridge fill-finish operations. The partnership is expected to strengthen Shantha Biologics' position in the global pharmaceutical outsourcing market.
